Infection is considered life-long, as the virus becomes latent in sacral nerve ganglia, and may result in recurrent genital lesions
External resources SUSTAIN-6 Trial - New England Journal of Medicine : The landmark cardiovascular outcomes trial showing 26% MACE reduction with semaglutide in high-risk type 2 diabetes patients, providing foundational evidence for semaglutide cardiovascular benefit
This technique applies identically whether you are working with tirzepatide, semaglutide , or any other injectable GLP-1 peptide
Jump to: What the trial found | How the pill compares to injectable Wegovy | How oral semaglutide works differently | Side effects and safety | Limitations to keep in mind | What this means for the UK | Take home message A daily pill containing semaglutide, the same active ingredient in Wegovy, produced an average weight loss of 13.6% over 64 weeks in a clinical trial of adults with obesity or overweight
Management strategies should address modifiable risk factors while continuing semaglutide if it is providing metabolic benefits
More in section 5